Archives20242023202220212020201920182017201620152014201320122011 August 13, 2013UPDATE: Cancer Programme IPP-204106 Read More August 12, 2013FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities Read More July 08, 2013Appointment of Scientific Advisory Board Read More May 21, 2013ImmuPharma secures £50M financing facility for Lupuzor Phase III Read More April 08, 2013Immupharma gets Lupuzor research boost Read More February 28, 2013ImmuPharma Commences Trading on the Stuttgart Stock Exchange Read More January 28, 2013CNRS Confirms Lupuzor’sTM Effectiveness Read More November 20, 2012ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C. Read More November 15, 2012ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Read More October 08, 2012Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing Read More September 07, 2012ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012 Read More July 13, 2012ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012 Read More 1…19202122
August 12, 2013FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities Read More
November 20, 2012ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C. Read More
November 15, 2012ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Read More
October 08, 2012Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing Read More
September 07, 2012ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012 Read More
July 13, 2012ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012 Read More
